U.S. market Closed. Opens in 13 hours 51 minutes

HQL | Tekla Life Sciences Investors Stock Fundamentals

(Stock Exchange: NYSE)
Analyzing fundamentals for HQL we got that it has weak fundamentals where Valuation is considered to be fairly valued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak.

Valuation (57%)

Company Industry
P/E Ratio (TTM) 10.51 37.90
PEG Ratio (TTM) 0.21 5.33
P/S Ratio (TTM) 12.89 66.51
P/B Ratio (TTM) 0.92 72.67
P/FCF Ratio (TTM) N/A 83.40
Price to 5YR AVG Earnings Ratio 48.40 13.84
Price to 5YR AVG FCF Ratio -1,498,148,254.95 46.20

Profitability (43%)

Company Industry
ROA (TTM) 8.78% 648.99%
ROE (TTM) 9.07% 10.18%
Net Profit Margin (TTM) 122.69% -11.93%
ROIC 5YR AVG 1.59% 15.72%

Growth (25%)

4QTR AVG 3YR AVG 5YR AVG
EPS 70.55% -41.96% -51.70%
Revenue 255.66% -33.55% -47.01%
Net Income 71.39% -39.61% -51.91%
Cash Flow -25.00% N/A -20.00%

Health (23%)

Company Industry
Current Ratio (TTM) 0.20 5.01
Quick Ratio (TTM) 15.92 4.44
D/E Ratio (TTM) N/A 0.85
Interest Coverage (TTM) N/A 8.93
Piotroski F-Score 4 6
Altman Z-Score N/A 6.21
LTL to 5YR AVG FCF N/A 7.60
Shares Outstanding Growth 5YR AVG 2.85% 3.56%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙